Compare Enveric Biosciences Inc (ENVB) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs BlackRock TCP Capital Corp — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while BlackRock TCP Capital Corp trades at $4.04 (market cap $332.25M). The key difference: BlackRock TCP Capital Corp is far larger — about 49.7× Enveric Biosciences Inc's market cap, and BlackRock TCP Capital Corp pays a 19.19% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and BlackRock TCP Capital Corp for 88 Days on average.
| ENVB | TCPC | |
|---|---|---|
Market Cap | $6.69M | $332.25M |
Volume | 41,141 | 567,148 |
Sector | Health | Financials |
52-Week High | $10.80 | $6.20 |
52-Week Low | $1.27 | $3.13 |
Typical Hold Time | 14 Days | 88 Days |
Enterprise Value | -$1.60M | $1.08B |
Dividend Yield | — | 19.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
TCPC trades at $3.94, down 1.25% with a bearish technical outlook. The company reported negative revenue and net income trends from 2024-2026, though recent Q2 2026 earnings beat expectations. A strategic portfolio sale of $523 million aims to reduce leverage and improve liquidity. Analyst sentiment is mixed with 30.77% buy ratings but predominantly hold recommendations.
TCPC faces significant fundamental challenges with declining revenue and negative profitability metrics. The ongoing strategic review and portfolio cleanup may offer long-term value, but investors should weigh the high dividend yield against persistent negative cash flow and earnings trends. Key risks include execution of the strategic review and broader private credit market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
